NGNE · TickerCove

NGNENeurogene Inc.Healthcare · Biotechnologyas of 2026-09-16

Horizon

Issued 2026-09-16 at $34.67 · now $34.67 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, NGNE has typically landed between $22.92 and $49.73 — a range of −33.9% to +43.4% from the issuance price $34.67.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.

Actual close
Typical path (median)
Middle 50% of outcomes
90% range

3,126 overlapping 1 month windows · 2014-03-07 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($34.67) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

52-week range$34.67 · 69% of range

$16.37 low$42.84 high

Trailing 52 weeks to 2026-09-16 — factual context, not a signal.

Base rate up · monthiClimatology base rate that a US-listed stock rises over a month, with its 90% CI and ≈1,408 effective observations. Not a call on this stock — we have no evidence its odds differ.

53.9%

90% CI 51.7%–56.1%

Distribution · month iiThe price-anchored range: typical move (median), and the p90 downside/upside — 90% of similar periods stayed inside these. Ranges, not a prediction of direction.

−1.8%

typical move · IQR 29.6%

−33.9%worst (p90)+43.4%best (p90)

Insider convictioniOpen-market common-stock purchases by company insiders in the last 90 days (grants and option exercises excluded). Historical tendency, not advice — detail below.

conviction buys

0 open-market sales

Congress disclosuresiRecent disclosed congressional trades for this company. Purchase clusters (≥2 members buying within 90 days) historically preceded a modestly higher forward return (+32 bp/mo in 2022–2026, +45 bp/mo in 2015–2021) — a descriptive tendency, not a forecast input. Detail below.

0 buys · 0 sells · 0 members

cluster tilt persisted, ~halved after 2021

Where NGNE has typically landed a month from the 2026-09-16 close of $34.67 — the range is history, not a prediction.

now $34.67 (+0.0%)
typical $34.04 (-1.8%)
middle 50% $28.91–$39.17
90% range $22.92–$49.73

Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 3,126 windows spanning 2014-03-07 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.

Start	Return	Max drop	Max rise
3 worst
2018-05-29	−82.8%	−82.8%	+19.7%
2018-06-13	−82.6%	−84.4%	+8.2%
2018-05-31	−82.1%	−84.2%	+9.6%
3 best
2015-07-24	+1111.9%	−3.3%	+1365.6%
2015-07-27	+1094.5%	+0.0%	+1415.8%
2015-07-14	+1070.9%	−22.8%	+1070.9%

3,126 overlapping windows · 2014-03-07 – 2026-09-16 · not cherry-picked

Pending catalysts

November 2028 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Gene Therapy Study for Children With CLN5 Batten Disease (source, as of 2026-08-14)
December 2029 — Trial primary completion: Phase 3 primary completion: A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome (source, as of 2026-08-14)

Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.

Seasonality · by month i

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~13 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.

Jan

58%

+3.6%

n=12

Feb

42%

−1.9%

n=12

Mar

42%

+2.2%

n=12

Apr

31%

−4.8%

n=13

May

54%

+0.8%

n=13

Jun

46%

−5.8%

n=13

Jul

54%

−4.7%

n=13

Aug

85%

+72.5%

n=13

Sep

23%

−6.4%

n=13

Oct

42%

+2.0%

n=12

Nov

42%

+0.0%

n=12

Dec

58%

+14.7%

n=12

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Date	Person	Role	Action	Shares @ price	Value	Ownership Δ	vs S&P 1m	vs S&P 6m	Owned after	Filing
2026-07-07	Cvijic Christine Mikail	director	Sale	4,200 @ $36.13	$152K	−4.8% of holding	−5.2%	not yet — horizon still open	84,040	Form 4 · filed same day
2026-07-06	Cvijic Christine Mikail	director	Sale	600 @ $36.02	$22K	−0.7% of holding	+3.0%	not yet — horizon still open	88,240	Form 4 · filed 1 day after the trade
2026-07-02	Cvijic Christine Mikail	director	Sale	2,531 @ $34.58	$88K	−2.7% of holding	−8.7%	not yet — horizon still open	90,370	Form 4 · filed same day
2026-07-02	Cvijic Christine Mikail	director	Sale	1,530 @ $35.23	$54K	−1.7% of holding	−8.7%	not yet — horizon still open	88,840	Form 4 · filed same day
2026-07-01	Cvijic Christine Mikail	director	Sale	739 @ $34.06	$25K	−0.8% of holding	−3.1%	not yet — horizon still open	92,901	Form 4 · filed 1 day after the trade
2026-05-06	Cvijic Christine Mikail	director	Sale	4,800 @ $32.44	$156K	−4.9% of holding	−18.6%	not yet — horizon still open	93,640	Form 4 · filed 2 days after the trade
2026-05-06	Cvijic Christine Mikail	director	Sale	4,800 @ $30.07	$144K	−4.6% of holding	−18.6%	not yet — horizon still open	98,440	Form 4 · filed 2 days after the trade
2026-03-26	McMinn Rachel	director	Sale	3,352 @ $22.07	$74K	−0.2% of holding	+15.5%	not yet — horizon still open	1,344,307	Form 4 · filed 4 days after the trade
2026-03-26	Cvijic Christine Mikail	director	Sale	2,558 @ $21.62	$55K	−2.4% of holding	+15.5%	not yet — horizon still open	103,240	Form 4 · filed 4 days after the trade
2026-03-26	Jordan Julie	officer	Sale	828 @ $21.89	$18K	−6.2% of holding	+15.5%	not yet — horizon still open	12,472	Form 4 · filed 4 days after the trade
2026-03-13	Cobb Stuart	officer	Sale	3,991 @ $20.41	$81K	−10.7% of holding	−8.6%	+48.2%	33,303	Form 4 · filed 4 days after the trade
2026-03-13	Cobb Stuart	officer	Sale	2,658 @ $21.34	$57K	−8.0% of holding	−8.6%	+48.2%	30,645	Form 4 · filed 4 days after the trade
2026-03-13	Cvijic Christine Mikail	director	Sale	2,387 @ $20.42	$49K	−2.2% of holding	−8.6%	+48.2%	107,456	Form 4 · filed 4 days after the trade
2026-03-13	Cvijic Christine Mikail	director	Sale	1,395 @ $21.25	$30K	−1.3% of holding	−8.6%	+48.2%	106,061	Form 4 · filed 4 days after the trade
2026-03-13	Cvijic Christine Mikail	director	Sale	263 @ $22.02	$6K	−0.2% of holding	−8.6%	+48.2%	105,798	Form 4 · filed 4 days after the trade
2026-03-13	Cobb Stuart	officer	Sale	148 @ $22.08	$3K	−0.5% of holding	−8.6%	+48.2%	30,497	Form 4 · filed 4 days after the trade
2026-02-27	Cvijic Christine Mikail	director	Sale	4,800 @ $25.11	$121K	−4.2% of holding	−10.2%	+43.0%	109,843	Form 4 · filed 4 days after the trade
2025-05-14	Cobb Stuart	officer	Sale	6,797 @ $15.15	$103K	−24.6% of holding	+28.2%	+87.2%	20,794	Form 4 · filed 1 day after the trade
2025-03-13	Cvijic Christine Mikail	director	Sale	4,501 @ $16.94	$76K	−5.9% of holding	−31.6%	−6.8%	72,343	Form 4 · filed 4 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

26 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

Date	Person	Role	Action	Shares	Owned after	Filing
2026-05-05	Shafer Christina	officer	Award / grant	120,000	120,000	Form 4
2026-02-20	Cobb Stuart	officer	Award / grant	16,500	37,294	Form 4
2026-02-20	Cvijic Christine Mikail	director	Award / grant	131,900	131,900	Form 4
2026-02-20	Cvijic Christine Mikail	director	Award / grant	22,000	114,643	Form 4
2026-02-20	Freedland Cory S.	director	Award / grant	12,050	12,050	Form 4
2026-02-20	McMinn Rachel	director	Award / grant	25,900	1,347,659	Form 4
2026-02-20	McMinn Rachel	director	Award / grant	155,100	155,100	Form 4
2026-02-20	BAFFI ROBERT	director	Award / grant	12,050	12,050	Form 4
2026-02-20	PALEKAR ROHAN	director	Award / grant	12,050	12,050	Form 4
2026-02-20	Jordan Julie	officer	Award / grant	4,900	13,300	Form 4
2026-02-20	Jordan Julie	officer	Award / grant	29,600	29,600	Form 4
2026-02-20	Woods Keith	director	Award / grant	12,050	12,050	Form 4
2026-02-20	Noonberg Sarah B.	director	Award / grant	12,050	12,050	Form 4
2025-06-12	Freedland Cory S.	director	Award / grant	12,050	12,050	Form 4
2025-06-12	PALEKAR ROHAN	director	Award / grant	12,050	12,050	Form 4
2025-06-12	Woods Robert Keith	director	Award / grant	12,050	12,050	Form 4
2025-06-12	BAFFI ROBERT	director	Award / grant	12,050	12,050	Form 4
2025-06-12	Noonberg Sarah B.	director	Award / grant	12,050	12,050	Form 4
2025-03-26	McMinn Rachel	director	Award / grant	23,900	1,274,259	Form 4
2025-03-26	McMinn Rachel	director	Award / grant	143,500	143,500	Form 4
2025-03-26	Jordan Julie	officer	Award / grant	8,400	8,400	Form 4
2025-03-26	Jordan Julie	officer	Award / grant	50,300	50,300	Form 4
2025-03-26	Cobb Stuart	officer	Award / grant	7,200	27,591	Form 4
2025-03-26	Cobb Stuart	officer	Award / grant	42,900	42,900	Form 4
2025-03-26	Cvijic Christine Mikail	director	Award / grant	20,300	92,643	Form 4
2025-03-26	Cvijic Christine Mikail	director	Award / grant	122,000	122,000	Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Resolves in i

28d remaining

2026-09-173% elapsed2026-10-15

Logged immutably 2026-09-17; scored automatically on 2026-10-15 — no edits, ever.

Earnings & context analysis

These panels are being prepared. They are generated by multiple language models, checked, and stored before display — never written live for a page view. Until a model panel has been generated and reviewed for a company, nothing is shown here, honestly, rather than a placeholder.

Calibration i

Every forecast is logged when made and scored when the month is up. The record is shown from the day it starts — young and honest.

How scoring works →

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.

Pending catalysts

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

Reported insider & political trades

Congressional disclosures

Seasonality · by month i